Intelligence Feed event · Equity · 2026-10-07

    Vaxcyte Prices $1 Billion Concurrent Common Stock and Convertible Debt Offerings

    Question

    Vaxcyte Prices $1 Billion Concurrent Common Stock and Convertible Debt Offerings

    Direct answer

    Clinical-stage vaccine biopharma Vaxcyte finalized terms on a $1 billion capital raise. The deal combines 7.4 million common shares priced at $64.00 with pre-funded warrants alongside $500 million in 1.50% convertible senior notes maturing in 2032. The capital significantly bolsters balance sheet liquidity for Phase 3 trials and regulatory manufacturing readiness, while introducing near-term secondary supply and potential convertible dilution.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte Prices $1 Billion Concurrent Common Stock and Convertible Debt Offerings”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1-billion-concurrent-common-stock-and-convertible-debt-offerings-fe3265

    EQUITY
    Vaxcyte Prices $1 Billion Concurrent Common Stock and Convertible Debt Offerings
    Clinical-stage vaccine biopharma Vaxcyte finalized terms on a $1 billion capital raise. The deal combines 7.4 million common shares priced at $64.00 with pre-funded warrants alongside $500 million in 1.50% convertible senior notes maturing in 2032. The capital significantly bolsters balance sheet liquidity for Phase 3 trials and regulatory manufacturing readiness, while introducing near-term secondary supply and potential convertible dilution.
    PCVX
    Impact
    65
    OCT 7
    SIG
    95%
    PCVX
    Vaxcyte Prices $1 Billion Concurrent Common Stock and Convertible Debt Offerings
    Clinical-stage vaccine biopharma Vaxcyte finalized terms on a $1 billion capital raise. The deal combines 7.4 million common shares priced at $64.00 with pre-funded warrants alongside $500 million in 1.50% convertible senior notes maturing in 2032. The capital significantly bolsters balance sheet liquidity for Phase 3 trials and regulatory manufacturing readiness, while introducing near-term secondary supply and potential convertible dilution.
    → Equity issuance at $64.00 and $500 million in convertible debt creates immediate equity dilution while extending PCVX clinical pipeline runway.
    Impact
    Clinical-stage vaccine biopharma Vaxcyte finalized terms on a $1 billion capital raise. The deal combines 7.4 million common shares priced at $64.00 with pre-funded warrants alongside $500 million in 1.50% convertible senior notes maturing in 2032. The capital significantly bolsters balance sheet liquidity for Phase 3 trials and regulatory manufacturing readiness, while introducing near-term secondary supply and potential convertible dilution.
    Affected
    PCVX
    Transmission
    Equity issuance at $64.00 and $500 million in convertible debt creates immediate equity dilution while extending PCVX clinical pipeline runway.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity dilution and convertible note supply overhang balanced by extended cash runwayMixed1-5dVaxcyte announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds at $64.00 per share.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXMixed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month